Lunai Bioworks Regains Nasdaq $1.00 Bid-Price Compliance, Faces One-Year Monitoring
Summary
Lunai Bioworks has officially regained compliance with Nasdaq's $1.00 minimum bid-price rule, removing an immediate delisting threat. This follows the 1-for-8 reverse stock split executed on May 22, 2026, which was approved by shareholders to address prior delisting notices. While avoiding delisting is critical for investor confidence and liquidity, Nasdaq has imposed a one-year Panel monitoring period. This means Lunai will not receive additional cure periods if its stock price falls below $1.00 again during this time, highlighting continued fragility.
At the time of this announcement, LNAI was trading at $2.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.9M. The 52-week trading range was $1.21 to $31.75. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.